nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—ABCB1—melanoma	0.171	1	CbGaD
Dipyridamole—PDE5A—clitoris—melanoma	0.0302	0.133	CbGeAlD
Dipyridamole—PDE6G—optic choroid—melanoma	0.0206	0.0906	CbGeAlD
Dipyridamole—PDE8B—leg—melanoma	0.0118	0.0518	CbGeAlD
Dipyridamole—PDE8B—hindlimb—melanoma	0.0105	0.0462	CbGeAlD
Dipyridamole—PDE8B—appendage—melanoma	0.00903	0.0397	CbGeAlD
Dipyridamole—PDE6A—eye—melanoma	0.00772	0.0339	CbGeAlD
Dipyridamole—PDE6A—retina—melanoma	0.00765	0.0336	CbGeAlD
Dipyridamole—PDE6C—eye—melanoma	0.00732	0.0321	CbGeAlD
Dipyridamole—PDE6C—retina—melanoma	0.00725	0.0318	CbGeAlD
Dipyridamole—PDE6A—mammalian vulva—melanoma	0.00613	0.0269	CbGeAlD
Dipyridamole—PDE6B—eye—melanoma	0.00464	0.0204	CbGeAlD
Dipyridamole—PDE6B—retina—melanoma	0.0046	0.0202	CbGeAlD
Dipyridamole—PDE6A—head—melanoma	0.00438	0.0192	CbGeAlD
Dipyridamole—PDE6H—eye—melanoma	0.00431	0.0189	CbGeAlD
Dipyridamole—PDE6H—retina—melanoma	0.00428	0.0188	CbGeAlD
Dipyridamole—PDE6C—head—melanoma	0.00416	0.0182	CbGeAlD
Dipyridamole—PDE6G—eye—melanoma	0.00415	0.0182	CbGeAlD
Dipyridamole—PDE6G—retina—melanoma	0.00412	0.0181	CbGeAlD
Dipyridamole—PDE8B—neck—melanoma	0.0036	0.0158	CbGeAlD
Dipyridamole—PDE5A—endothelium—melanoma	0.00334	0.0147	CbGeAlD
Dipyridamole—PDE5A—blood vessel—melanoma	0.00308	0.0135	CbGeAlD
Dipyridamole—PDE1C—head—melanoma	0.00307	0.0135	CbGeAlD
Dipyridamole—ABCC5—hair follicle—melanoma	0.00301	0.0132	CbGeAlD
Dipyridamole—PDE6B—head—melanoma	0.00263	0.0116	CbGeAlD
Dipyridamole—PDE6H—head—melanoma	0.00245	0.0108	CbGeAlD
Dipyridamole—PDE8A—eye—melanoma	0.00241	0.0106	CbGeAlD
Dipyridamole—PDE6G—head—melanoma	0.00236	0.0103	CbGeAlD
Dipyridamole—PDE2A—mammalian vulva—melanoma	0.00223	0.00977	CbGeAlD
Dipyridamole—PDE7A—head—melanoma	0.00218	0.00958	CbGeAlD
Dipyridamole—PDE1C—lymph node—melanoma	0.00215	0.00945	CbGeAlD
Dipyridamole—PRUNE—lymph node—melanoma	0.00194	0.00852	CbGeAlD
Dipyridamole—PDE8A—mammalian vulva—melanoma	0.00191	0.00838	CbGeAlD
Dipyridamole—PDE7B—head—melanoma	0.00191	0.00838	CbGeAlD
Dipyridamole—PDE6D—lymph node—melanoma	0.00187	0.00823	CbGeAlD
Dipyridamole—PDE6G—lymph node—melanoma	0.00165	0.00725	CbGeAlD
Dipyridamole—PDE5A—eye—melanoma	0.00164	0.00721	CbGeAlD
Dipyridamole—PDE5A—retina—melanoma	0.00163	0.00714	CbGeAlD
Dipyridamole—PDE2A—head—melanoma	0.00159	0.00699	CbGeAlD
Dipyridamole—PDE10A—head—melanoma	0.00159	0.00699	CbGeAlD
Dipyridamole—PDE1B—head—melanoma	0.00158	0.00693	CbGeAlD
Dipyridamole—ADA—mammalian vulva—melanoma	0.00157	0.0069	CbGeAlD
Dipyridamole—PDE8B—head—melanoma	0.00152	0.00667	CbGeAlD
Dipyridamole—ABCC5—retina—melanoma	0.00149	0.00653	CbGeAlD
Dipyridamole—PDE7B—lymph node—melanoma	0.00134	0.00586	CbGeAlD
Dipyridamole—PDE1A—head—melanoma	0.00132	0.00581	CbGeAlD
Dipyridamole—ADA—head—melanoma	0.00112	0.00494	CbGeAlD
Dipyridamole—PDE2A—lymph node—melanoma	0.00111	0.00489	CbGeAlD
Dipyridamole—PDE10A—lymph node—melanoma	0.00111	0.00489	CbGeAlD
Dipyridamole—PDE1B—lymph node—melanoma	0.0011	0.00485	CbGeAlD
Dipyridamole—SLC29A1—mammalian vulva—melanoma	0.00109	0.0048	CbGeAlD
Dipyridamole—PDE8B—lymph node—melanoma	0.00106	0.00467	CbGeAlD
Dipyridamole—PDE3B—lymph node—melanoma	0.00104	0.00456	CbGeAlD
Dipyridamole—Bone disorder—Docetaxel—melanoma	0.001	0.00533	CcSEcCtD
Dipyridamole—Bronchospasm—Bleomycin—melanoma	0.000995	0.00529	CcSEcCtD
Dipyridamole—Myalgia—Vemurafenib—melanoma	0.00099	0.00527	CcSEcCtD
Dipyridamole—Arthralgia—Vemurafenib—melanoma	0.00099	0.00527	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000983	0.00523	CcSEcCtD
Dipyridamole—PDE8A—lymph node—melanoma	0.000957	0.0042	CbGeAlD
Dipyridamole—Anaphylactic shock—Vemurafenib—melanoma	0.000949	0.00505	CcSEcCtD
Dipyridamole—Dysphagia—Dactinomycin—melanoma	0.000943	0.00502	CcSEcCtD
Dipyridamole—PDE5A—head—melanoma	0.000932	0.00409	CbGeAlD
Dipyridamole—Nervous system disorder—Vemurafenib—melanoma	0.000931	0.00495	CcSEcCtD
Dipyridamole—PDE1A—lymph node—melanoma	0.000926	0.00407	CbGeAlD
Dipyridamole—Skin disorder—Vemurafenib—melanoma	0.000922	0.00491	CcSEcCtD
Dipyridamole—Injection site reaction—Docetaxel—melanoma	0.000899	0.00478	CcSEcCtD
Dipyridamole—Acute coronary syndrome—Bleomycin—melanoma	0.000889	0.00473	CcSEcCtD
Dipyridamole—Hypotension—Vemurafenib—melanoma	0.000887	0.00472	CcSEcCtD
Dipyridamole—Myocardial infarction—Bleomycin—melanoma	0.000884	0.0047	CcSEcCtD
Dipyridamole—Dysphagia—Carmustine—melanoma	0.000883	0.0047	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000865	0.0046	CcSEcCtD
Dipyridamole—Dysphagia—Temozolomide—melanoma	0.000853	0.00454	CcSEcCtD
Dipyridamole—Sweating increased—Temozolomide—melanoma	0.000831	0.00442	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Vemurafenib—melanoma	0.000819	0.00436	CcSEcCtD
Dipyridamole—Fatigue—Vemurafenib—melanoma	0.000818	0.00436	CcSEcCtD
Dipyridamole—Haemoglobin—Bleomycin—melanoma	0.000814	0.00433	CcSEcCtD
Dipyridamole—Haemorrhage—Bleomycin—melanoma	0.000809	0.00431	CcSEcCtD
Dipyridamole—Hypoaesthesia—Bleomycin—melanoma	0.000805	0.00429	CcSEcCtD
Dipyridamole—Pulmonary oedema—Docetaxel—melanoma	0.000805	0.00428	CcSEcCtD
Dipyridamole—ADA—lymph node—melanoma	0.000787	0.00346	CbGeAlD
Dipyridamole—SLC29A1—head—melanoma	0.000782	0.00343	CbGeAlD
Dipyridamole—PDE4A—lymph node—melanoma	0.000767	0.00337	CbGeAlD
Dipyridamole—Hepatitis—Dactinomycin—melanoma	0.000755	0.00402	CcSEcCtD
Dipyridamole—Flushing—Bleomycin—melanoma	0.000751	0.004	CcSEcCtD
Dipyridamole—Pharyngitis—Dactinomycin—melanoma	0.000749	0.00399	CcSEcCtD
Dipyridamole—Chills—Bleomycin—melanoma	0.000726	0.00387	CcSEcCtD
Dipyridamole—Alopecia—Bleomycin—melanoma	0.000715	0.00381	CcSEcCtD
Dipyridamole—Haemoglobin—Carmustine—melanoma	0.00071	0.00378	CcSEcCtD
Dipyridamole—Haemorrhage—Carmustine—melanoma	0.000707	0.00376	CcSEcCtD
Dipyridamole—Hypoaesthesia—Carmustine—melanoma	0.000703	0.00374	CcSEcCtD
Dipyridamole—Hot flush—Docetaxel—melanoma	0.000702	0.00373	CcSEcCtD
Dipyridamole—Flushing—Dactinomycin—melanoma	0.000701	0.00373	CcSEcCtD
Dipyridamole—Hypersensitivity—Vemurafenib—melanoma	0.000699	0.00372	CcSEcCtD
Dipyridamole—Menopausal symptoms—Docetaxel—melanoma	0.000696	0.0037	CcSEcCtD
Dipyridamole—Atrial fibrillation—Docetaxel—melanoma	0.000693	0.00369	CcSEcCtD
Dipyridamole—Haemoglobin—Temozolomide—melanoma	0.000686	0.00365	CcSEcCtD
Dipyridamole—Hepatitis—Temozolomide—melanoma	0.000683	0.00363	CcSEcCtD
Dipyridamole—Haemorrhage—Temozolomide—melanoma	0.000683	0.00363	CcSEcCtD
Dipyridamole—Asthenia—Vemurafenib—melanoma	0.000681	0.00363	CcSEcCtD
Dipyridamole—ABCB1—blood vessel—melanoma	0.000681	0.00299	CbGeAlD
Dipyridamole—Hypoaesthesia—Temozolomide—melanoma	0.000679	0.00362	CcSEcCtD
Dipyridamole—Pharyngitis—Temozolomide—melanoma	0.000678	0.00361	CcSEcCtD
Dipyridamole—Chills—Dactinomycin—melanoma	0.000677	0.00361	CcSEcCtD
Dipyridamole—Pruritus—Vemurafenib—melanoma	0.000672	0.00357	CcSEcCtD
Dipyridamole—Alopecia—Dactinomycin—melanoma	0.000667	0.00355	CcSEcCtD
Dipyridamole—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.000656	0.00349	CcSEcCtD
Dipyridamole—Flushing—Carmustine—melanoma	0.000656	0.00349	CcSEcCtD
Dipyridamole—Ill-defined disorder—Bleomycin—melanoma	0.000654	0.00348	CcSEcCtD
Dipyridamole—PDE5A—lymph node—melanoma	0.000652	0.00286	CbGeAlD
Dipyridamole—Anaemia—Bleomycin—melanoma	0.000651	0.00347	CcSEcCtD
Dipyridamole—Diarrhoea—Vemurafenib—melanoma	0.000649	0.00346	CcSEcCtD
Dipyridamole—Migraine—Docetaxel—melanoma	0.000646	0.00344	CcSEcCtD
Dipyridamole—Tinnitus—Temozolomide—melanoma	0.000637	0.00339	CcSEcCtD
Dipyridamole—Malaise—Bleomycin—melanoma	0.000635	0.00338	CcSEcCtD
Dipyridamole—PDE3A—lymph node—melanoma	0.000635	0.00279	CbGeAlD
Dipyridamole—Flushing—Temozolomide—melanoma	0.000634	0.00337	CcSEcCtD
Dipyridamole—Cardiac disorder—Temozolomide—melanoma	0.000634	0.00337	CcSEcCtD
Dipyridamole—Arrhythmia—Carmustine—melanoma	0.000631	0.00336	CcSEcCtD
Dipyridamole—Dizziness—Vemurafenib—melanoma	0.000628	0.00334	CcSEcCtD
Dipyridamole—Alopecia—Carmustine—melanoma	0.000624	0.00332	CcSEcCtD
Dipyridamole—Angiopathy—Temozolomide—melanoma	0.000619	0.0033	CcSEcCtD
Dipyridamole—Immune system disorder—Temozolomide—melanoma	0.000617	0.00328	CcSEcCtD
Dipyridamole—Mediastinal disorder—Temozolomide—melanoma	0.000615	0.00328	CcSEcCtD
Dipyridamole—Cough—Bleomycin—melanoma	0.000615	0.00327	CcSEcCtD
Dipyridamole—Chills—Temozolomide—melanoma	0.000613	0.00326	CcSEcCtD
Dipyridamole—Ill-defined disorder—Dactinomycin—melanoma	0.00061	0.00325	CcSEcCtD
Dipyridamole—Anaemia—Dactinomycin—melanoma	0.000607	0.00323	CcSEcCtD
Dipyridamole—Vomiting—Vemurafenib—melanoma	0.000603	0.00321	CcSEcCtD
Dipyridamole—Alopecia—Temozolomide—melanoma	0.000603	0.00321	CcSEcCtD
Dipyridamole—Myalgia—Bleomycin—melanoma	0.0006	0.00319	CcSEcCtD
Dipyridamole—Chest pain—Bleomycin—melanoma	0.0006	0.00319	CcSEcCtD
Dipyridamole—Orthostatic hypotension—Docetaxel—melanoma	0.000599	0.00319	CcSEcCtD
Dipyridamole—Abdominal pain upper—Docetaxel—melanoma	0.000599	0.00319	CcSEcCtD
Dipyridamole—Rash—Vemurafenib—melanoma	0.000598	0.00319	CcSEcCtD
Dipyridamole—Dermatitis—Vemurafenib—melanoma	0.000598	0.00318	CcSEcCtD
Dipyridamole—ABCC5—lymph node—melanoma	0.000597	0.00262	CbGeAlD
Dipyridamole—Back pain—Carmustine—melanoma	0.000595	0.00317	CcSEcCtD
Dipyridamole—Headache—Vemurafenib—melanoma	0.000595	0.00317	CcSEcCtD
Dipyridamole—Discomfort—Bleomycin—melanoma	0.000593	0.00315	CcSEcCtD
Dipyridamole—Malaise—Dactinomycin—melanoma	0.000593	0.00315	CcSEcCtD
Dipyridamole—Cramp muscle—Docetaxel—melanoma	0.000591	0.00315	CcSEcCtD
Dipyridamole—ABCC4—head—melanoma	0.000591	0.00259	CbGeAlD
Dipyridamole—Dysgeusia—Temozolomide—melanoma	0.000582	0.0031	CcSEcCtD
Dipyridamole—Tremor—Carmustine—melanoma	0.000576	0.00307	CcSEcCtD
Dipyridamole—Anaphylactic shock—Bleomycin—melanoma	0.000575	0.00306	CcSEcCtD
Dipyridamole—Oedema—Bleomycin—melanoma	0.000575	0.00306	CcSEcCtD
Dipyridamole—Back pain—Temozolomide—melanoma	0.000575	0.00306	CcSEcCtD
Dipyridamole—Anaemia—Carmustine—melanoma	0.000568	0.00303	CcSEcCtD
Dipyridamole—Dysphagia—Docetaxel—melanoma	0.000567	0.00302	CcSEcCtD
Dipyridamole—Nausea—Vemurafenib—melanoma	0.000564	0.003	CcSEcCtD
Dipyridamole—Thrombocytopenia—Bleomycin—melanoma	0.000563	0.003	CcSEcCtD
Dipyridamole—Myalgia—Dactinomycin—melanoma	0.000559	0.00298	CcSEcCtD
Dipyridamole—Bronchospasm—Docetaxel—melanoma	0.000558	0.00297	CcSEcCtD
Dipyridamole—Tremor—Temozolomide—melanoma	0.000557	0.00296	CcSEcCtD
Dipyridamole—Discomfort—Dactinomycin—melanoma	0.000553	0.00294	CcSEcCtD
Dipyridamole—Angina pectoris—Docetaxel—melanoma	0.000553	0.00294	CcSEcCtD
Dipyridamole—Ill-defined disorder—Temozolomide—melanoma	0.000551	0.00294	CcSEcCtD
Dipyridamole—Anaemia—Temozolomide—melanoma	0.000549	0.00292	CcSEcCtD
Dipyridamole—SLC29A1—lymph node—melanoma	0.000548	0.00241	CbGeAlD
Dipyridamole—Angioedema—Temozolomide—melanoma	0.000543	0.00289	CcSEcCtD
Dipyridamole—Hypotension—Bleomycin—melanoma	0.000537	0.00286	CcSEcCtD
Dipyridamole—Oedema—Dactinomycin—melanoma	0.000536	0.00285	CcSEcCtD
Dipyridamole—Malaise—Temozolomide—melanoma	0.000536	0.00285	CcSEcCtD
Dipyridamole—Vertigo—Temozolomide—melanoma	0.000534	0.00284	CcSEcCtD
Dipyridamole—Convulsion—Carmustine—melanoma	0.000533	0.00284	CcSEcCtD
Dipyridamole—Hypertension—Carmustine—melanoma	0.000531	0.00283	CcSEcCtD
Dipyridamole—Palpitations—Temozolomide—melanoma	0.000525	0.0028	CcSEcCtD
Dipyridamole—Thrombocytopenia—Dactinomycin—melanoma	0.000525	0.0028	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Bleomycin—melanoma	0.000524	0.00279	CcSEcCtD
Dipyridamole—Chest pain—Carmustine—melanoma	0.000524	0.00279	CcSEcCtD
Dipyridamole—Myalgia—Carmustine—melanoma	0.000524	0.00279	CcSEcCtD
Dipyridamole—Anxiety—Carmustine—melanoma	0.000522	0.00278	CcSEcCtD
Dipyridamole—Cough—Temozolomide—melanoma	0.000519	0.00276	CcSEcCtD
Dipyridamole—Paraesthesia—Bleomycin—melanoma	0.000516	0.00275	CcSEcCtD
Dipyridamole—Convulsion—Temozolomide—melanoma	0.000515	0.00274	CcSEcCtD
Dipyridamole—Hypertension—Temozolomide—melanoma	0.000513	0.00273	CcSEcCtD
Dipyridamole—Dyspnoea—Bleomycin—melanoma	0.000513	0.00273	CcSEcCtD
Dipyridamole—Arthralgia—Temozolomide—melanoma	0.000506	0.00269	CcSEcCtD
Dipyridamole—Myalgia—Temozolomide—melanoma	0.000506	0.00269	CcSEcCtD
Dipyridamole—Anxiety—Temozolomide—melanoma	0.000504	0.00268	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000503	0.00268	CcSEcCtD
Dipyridamole—Oedema—Carmustine—melanoma	0.000502	0.00267	CcSEcCtD
Dipyridamole—Discomfort—Temozolomide—melanoma	0.0005	0.00266	CcSEcCtD
Dipyridamole—Acute coronary syndrome—Docetaxel—melanoma	0.000499	0.00265	CcSEcCtD
Dipyridamole—Myocardial infarction—Docetaxel—melanoma	0.000496	0.00264	CcSEcCtD
Dipyridamole—Dry mouth—Temozolomide—melanoma	0.000495	0.00263	CcSEcCtD
Dipyridamole—Pain—Bleomycin—melanoma	0.000492	0.00262	CcSEcCtD
Dipyridamole—Thrombocytopenia—Carmustine—melanoma	0.000491	0.00262	CcSEcCtD
Dipyridamole—Tachycardia—Carmustine—melanoma	0.00049	0.00261	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000489	0.0026	CcSEcCtD
Dipyridamole—Oedema—Temozolomide—melanoma	0.000485	0.00258	CcSEcCtD
Dipyridamole—Anaphylactic shock—Temozolomide—melanoma	0.000485	0.00258	CcSEcCtD
Dipyridamole—Nervous system disorder—Temozolomide—melanoma	0.000476	0.00253	CcSEcCtD
Dipyridamole—Thrombocytopenia—Temozolomide—melanoma	0.000475	0.00253	CcSEcCtD
Dipyridamole—Feeling abnormal—Bleomycin—melanoma	0.000474	0.00252	CcSEcCtD
Dipyridamole—Skin disorder—Temozolomide—melanoma	0.000471	0.00251	CcSEcCtD
Dipyridamole—Hypotension—Carmustine—melanoma	0.000469	0.0025	CcSEcCtD
Dipyridamole—Hyperhidrosis—Temozolomide—melanoma	0.000469	0.0025	CcSEcCtD
Dipyridamole—Fatigue—Dactinomycin—melanoma	0.000462	0.00246	CcSEcCtD
Dipyridamole—Pain—Dactinomycin—melanoma	0.000459	0.00244	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Carmustine—melanoma	0.000457	0.00243	CcSEcCtD
Dipyridamole—Urticaria—Bleomycin—melanoma	0.000457	0.00243	CcSEcCtD
Dipyridamole—Haemoglobin—Docetaxel—melanoma	0.000456	0.00243	CcSEcCtD
Dipyridamole—Rhinitis—Docetaxel—melanoma	0.000455	0.00242	CcSEcCtD
Dipyridamole—Haemorrhage—Docetaxel—melanoma	0.000454	0.00242	CcSEcCtD
Dipyridamole—Hepatitis—Docetaxel—melanoma	0.000454	0.00242	CcSEcCtD
Dipyridamole—Hypoaesthesia—Docetaxel—melanoma	0.000452	0.0024	CcSEcCtD
Dipyridamole—Paraesthesia—Carmustine—melanoma	0.000451	0.0024	CcSEcCtD
Dipyridamole—Pharyngitis—Docetaxel—melanoma	0.000451	0.0024	CcSEcCtD
Dipyridamole—Dyspnoea—Carmustine—melanoma	0.000448	0.00238	CcSEcCtD
Dipyridamole—Somnolence—Carmustine—melanoma	0.000446	0.00238	CcSEcCtD
Dipyridamole—Feeling abnormal—Dactinomycin—melanoma	0.000442	0.00235	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Temozolomide—melanoma	0.000442	0.00235	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Dactinomycin—melanoma	0.000439	0.00233	CcSEcCtD
Dipyridamole—Paraesthesia—Temozolomide—melanoma	0.000436	0.00232	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Carmustine—melanoma	0.000433	0.00231	CcSEcCtD
Dipyridamole—Dyspnoea—Temozolomide—melanoma	0.000432	0.0023	CcSEcCtD
Dipyridamole—Somnolence—Temozolomide—melanoma	0.000431	0.0023	CcSEcCtD
Dipyridamole—Pain—Carmustine—melanoma	0.000429	0.00228	CcSEcCtD
Dipyridamole—Dyspepsia—Temozolomide—melanoma	0.000427	0.00227	CcSEcCtD
Dipyridamole—Abdominal pain—Dactinomycin—melanoma	0.000424	0.00226	CcSEcCtD
Dipyridamole—Hypersensitivity—Bleomycin—melanoma	0.000424	0.00226	CcSEcCtD
Dipyridamole—Flushing—Docetaxel—melanoma	0.000421	0.00224	CcSEcCtD
Dipyridamole—Cardiac disorder—Docetaxel—melanoma	0.000421	0.00224	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Temozolomide—melanoma	0.000419	0.00223	CcSEcCtD
Dipyridamole—Fatigue—Temozolomide—melanoma	0.000418	0.00223	CcSEcCtD
Dipyridamole—Pain—Temozolomide—melanoma	0.000415	0.00221	CcSEcCtD
Dipyridamole—Feeling abnormal—Carmustine—melanoma	0.000414	0.0022	CcSEcCtD
Dipyridamole—ABCC4—lymph node—melanoma	0.000414	0.00182	CbGeAlD
Dipyridamole—Asthenia—Bleomycin—melanoma	0.000413	0.0022	CcSEcCtD
Dipyridamole—Angiopathy—Docetaxel—melanoma	0.000412	0.00219	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Carmustine—melanoma	0.00041	0.00218	CcSEcCtD
Dipyridamole—Immune system disorder—Docetaxel—melanoma	0.00041	0.00218	CcSEcCtD
Dipyridamole—Mediastinal disorder—Docetaxel—melanoma	0.000409	0.00218	CcSEcCtD
Dipyridamole—Chills—Docetaxel—melanoma	0.000407	0.00217	CcSEcCtD
Dipyridamole—Pruritus—Bleomycin—melanoma	0.000407	0.00217	CcSEcCtD
Dipyridamole—Arrhythmia—Docetaxel—melanoma	0.000406	0.00216	CcSEcCtD
Dipyridamole—Alopecia—Docetaxel—melanoma	0.000401	0.00214	CcSEcCtD
Dipyridamole—Feeling abnormal—Temozolomide—melanoma	0.0004	0.00213	CcSEcCtD
Dipyridamole—Abdominal pain—Carmustine—melanoma	0.000397	0.00211	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Temozolomide—melanoma	0.000397	0.00211	CcSEcCtD
Dipyridamole—Hypersensitivity—Dactinomycin—melanoma	0.000395	0.0021	CcSEcCtD
Dipyridamole—Dysgeusia—Docetaxel—melanoma	0.000387	0.00206	CcSEcCtD
Dipyridamole—Urticaria—Temozolomide—melanoma	0.000385	0.00205	CcSEcCtD
Dipyridamole—Asthenia—Dactinomycin—melanoma	0.000385	0.00205	CcSEcCtD
Dipyridamole—Abdominal pain—Temozolomide—melanoma	0.000383	0.00204	CcSEcCtD
Dipyridamole—Back pain—Docetaxel—melanoma	0.000382	0.00204	CcSEcCtD
Dipyridamole—Muscle spasms—Docetaxel—melanoma	0.00038	0.00202	CcSEcCtD
Dipyridamole—Hypersensitivity—Carmustine—melanoma	0.00037	0.00197	CcSEcCtD
Dipyridamole—Diarrhoea—Dactinomycin—melanoma	0.000367	0.00195	CcSEcCtD
Dipyridamole—Vomiting—Bleomycin—melanoma	0.000366	0.00195	CcSEcCtD
Dipyridamole—Anaemia—Docetaxel—melanoma	0.000365	0.00194	CcSEcCtD
Dipyridamole—Rash—Bleomycin—melanoma	0.000363	0.00193	CcSEcCtD
Dipyridamole—Dermatitis—Bleomycin—melanoma	0.000362	0.00193	CcSEcCtD
Dipyridamole—Asthenia—Carmustine—melanoma	0.00036	0.00192	CcSEcCtD
Dipyridamole—ABCB1—retina—melanoma	0.000359	0.00158	CbGeAlD
Dipyridamole—Hypersensitivity—Temozolomide—melanoma	0.000357	0.0019	CcSEcCtD
Dipyridamole—Syncope—Docetaxel—melanoma	0.000354	0.00189	CcSEcCtD
Dipyridamole—Palpitations—Docetaxel—melanoma	0.000349	0.00186	CcSEcCtD
Dipyridamole—Asthenia—Temozolomide—melanoma	0.000348	0.00185	CcSEcCtD
Dipyridamole—Loss of consciousness—Docetaxel—melanoma	0.000347	0.00185	CcSEcCtD
Dipyridamole—Cough—Docetaxel—melanoma	0.000345	0.00184	CcSEcCtD
Dipyridamole—Diarrhoea—Carmustine—melanoma	0.000343	0.00183	CcSEcCtD
Dipyridamole—Pruritus—Temozolomide—melanoma	0.000343	0.00183	CcSEcCtD
Dipyridamole—Convulsion—Docetaxel—melanoma	0.000342	0.00182	CcSEcCtD
Dipyridamole—Nausea—Bleomycin—melanoma	0.000342	0.00182	CcSEcCtD
Dipyridamole—Hypertension—Docetaxel—melanoma	0.000341	0.00182	CcSEcCtD
Dipyridamole—Vomiting—Dactinomycin—melanoma	0.000341	0.00182	CcSEcCtD
Dipyridamole—Rash—Dactinomycin—melanoma	0.000338	0.0018	CcSEcCtD
Dipyridamole—Myalgia—Docetaxel—melanoma	0.000337	0.00179	CcSEcCtD
Dipyridamole—Arthralgia—Docetaxel—melanoma	0.000337	0.00179	CcSEcCtD
Dipyridamole—Chest pain—Docetaxel—melanoma	0.000337	0.00179	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000334	0.00178	CcSEcCtD
Dipyridamole—Dizziness—Carmustine—melanoma	0.000332	0.00177	CcSEcCtD
Dipyridamole—Diarrhoea—Temozolomide—melanoma	0.000332	0.00177	CcSEcCtD
Dipyridamole—Dry mouth—Docetaxel—melanoma	0.000329	0.00175	CcSEcCtD
Dipyridamole—Anaphylactic shock—Docetaxel—melanoma	0.000323	0.00172	CcSEcCtD
Dipyridamole—Oedema—Docetaxel—melanoma	0.000323	0.00172	CcSEcCtD
Dipyridamole—Dizziness—Temozolomide—melanoma	0.000321	0.00171	CcSEcCtD
Dipyridamole—Vomiting—Carmustine—melanoma	0.000319	0.0017	CcSEcCtD
Dipyridamole—Nausea—Dactinomycin—melanoma	0.000319	0.0017	CcSEcCtD
Dipyridamole—Shock—Docetaxel—melanoma	0.000317	0.00169	CcSEcCtD
Dipyridamole—Rash—Carmustine—melanoma	0.000316	0.00168	CcSEcCtD
Dipyridamole—Nervous system disorder—Docetaxel—melanoma	0.000316	0.00168	CcSEcCtD
Dipyridamole—Dermatitis—Carmustine—melanoma	0.000316	0.00168	CcSEcCtD
Dipyridamole—Thrombocytopenia—Docetaxel—melanoma	0.000316	0.00168	CcSEcCtD
Dipyridamole—Tachycardia—Docetaxel—melanoma	0.000315	0.00168	CcSEcCtD
Dipyridamole—Headache—Carmustine—melanoma	0.000314	0.00167	CcSEcCtD
Dipyridamole—Skin disorder—Docetaxel—melanoma	0.000313	0.00167	CcSEcCtD
Dipyridamole—Vomiting—Temozolomide—melanoma	0.000308	0.00164	CcSEcCtD
Dipyridamole—Rash—Temozolomide—melanoma	0.000306	0.00163	CcSEcCtD
Dipyridamole—Dermatitis—Temozolomide—melanoma	0.000306	0.00163	CcSEcCtD
Dipyridamole—Headache—Temozolomide—melanoma	0.000304	0.00162	CcSEcCtD
Dipyridamole—Hypotension—Docetaxel—melanoma	0.000301	0.0016	CcSEcCtD
Dipyridamole—Nausea—Carmustine—melanoma	0.000298	0.00159	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Docetaxel—melanoma	0.000294	0.00156	CcSEcCtD
Dipyridamole—Paraesthesia—Docetaxel—melanoma	0.00029	0.00154	CcSEcCtD
Dipyridamole—Nausea—Temozolomide—melanoma	0.000288	0.00153	CcSEcCtD
Dipyridamole—Dyspnoea—Docetaxel—melanoma	0.000288	0.00153	CcSEcCtD
Dipyridamole—ABCB1—mammalian vulva—melanoma	0.000287	0.00126	CbGeAlD
Dipyridamole—Somnolence—Docetaxel—melanoma	0.000287	0.00153	CcSEcCtD
Dipyridamole—Dyspepsia—Docetaxel—melanoma	0.000284	0.00151	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Docetaxel—melanoma	0.000279	0.00148	CcSEcCtD
Dipyridamole—Fatigue—Docetaxel—melanoma	0.000278	0.00148	CcSEcCtD
Dipyridamole—Pain—Docetaxel—melanoma	0.000276	0.00147	CcSEcCtD
Dipyridamole—Feeling abnormal—Docetaxel—melanoma	0.000266	0.00142	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Docetaxel—melanoma	0.000264	0.0014	CcSEcCtD
Dipyridamole—Abdominal pain—Docetaxel—melanoma	0.000255	0.00136	CcSEcCtD
Dipyridamole—Hypersensitivity—Docetaxel—melanoma	0.000238	0.00127	CcSEcCtD
Dipyridamole—Asthenia—Docetaxel—melanoma	0.000231	0.00123	CcSEcCtD
Dipyridamole—Pruritus—Docetaxel—melanoma	0.000228	0.00121	CcSEcCtD
Dipyridamole—Diarrhoea—Docetaxel—melanoma	0.000221	0.00117	CcSEcCtD
Dipyridamole—Dizziness—Docetaxel—melanoma	0.000213	0.00114	CcSEcCtD
Dipyridamole—ABCB1—head—melanoma	0.000206	0.000903	CbGeAlD
Dipyridamole—Vomiting—Docetaxel—melanoma	0.000205	0.00109	CcSEcCtD
Dipyridamole—Rash—Docetaxel—melanoma	0.000203	0.00108	CcSEcCtD
Dipyridamole—Dermatitis—Docetaxel—melanoma	0.000203	0.00108	CcSEcCtD
Dipyridamole—Headache—Docetaxel—melanoma	0.000202	0.00108	CcSEcCtD
Dipyridamole—Nausea—Docetaxel—melanoma	0.000192	0.00102	CcSEcCtD
Dipyridamole—ABCB1—lymph node—melanoma	0.000144	0.000632	CbGeAlD
Dipyridamole—PDE1A—Disease—STAT3—melanoma	8.82e-06	2.13e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—NRAS—melanoma	8.8e-06	2.13e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—NRAS—melanoma	8.8e-06	2.13e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—PIK3CA—melanoma	8.79e-06	2.13e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—FGF2—melanoma	8.78e-06	2.12e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—PIK3CA—melanoma	8.77e-06	2.12e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CDKN1B—melanoma	8.76e-06	2.12e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CB—melanoma	8.74e-06	2.11e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—STAT3—melanoma	8.74e-06	2.11e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MDM2—melanoma	8.74e-06	2.11e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—IL6—melanoma	8.74e-06	2.11e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—IL6—melanoma	8.74e-06	2.11e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IGF1—melanoma	8.73e-06	2.11e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TP53—melanoma	8.73e-06	2.11e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—NRAS—melanoma	8.72e-06	2.11e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—MAPK1—melanoma	8.69e-06	2.1e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—EGFR—melanoma	8.69e-06	2.1e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—MAPK1—melanoma	8.68e-06	2.1e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—EGFR—melanoma	8.68e-06	2.1e-05	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—AKT1—melanoma	8.67e-06	2.1e-05	CbGpPWpGaD
Dipyridamole—PDE3B—GPCR downstream signaling—AKT1—melanoma	8.66e-06	2.09e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—ERBB2—melanoma	8.61e-06	2.08e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	8.61e-06	2.08e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CASP3—melanoma	8.58e-06	2.07e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL2—melanoma	8.57e-06	2.07e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—IL6—melanoma	8.53e-06	2.06e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TP53—melanoma	8.51e-06	2.06e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CB—melanoma	8.5e-06	2.05e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—HRAS—melanoma	8.46e-06	2.05e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MAP2K1—melanoma	8.44e-06	2.04e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MAPK3—melanoma	8.43e-06	2.04e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MAPK3—melanoma	8.43e-06	2.04e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CXCL8—melanoma	8.4e-06	2.03e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CD—melanoma	8.39e-06	2.03e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CCND1—melanoma	8.36e-06	2.02e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—MAPK3—melanoma	8.35e-06	2.02e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—HRAS—melanoma	8.35e-06	2.02e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—HRAS—melanoma	8.34e-06	2.02e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	8.33e-06	2.01e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—PIK3CA—melanoma	8.31e-06	2.01e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CTNNB1—melanoma	8.27e-06	2e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTEN—melanoma	8.26e-06	2e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—PIK3CA—melanoma	8.25e-06	1.99e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MDM2—melanoma	8.21e-06	1.99e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—KRAS—melanoma	8.21e-06	1.98e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—KRAS—melanoma	8.2e-06	1.98e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CDKN1B—melanoma	8.2e-06	1.98e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MYC—melanoma	8.2e-06	1.98e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MYC—melanoma	8.2e-06	1.98e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CXCL8—melanoma	8.17e-06	1.97e-05	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—AKT1—melanoma	8.14e-06	1.97e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—HRAS—melanoma	8.13e-06	1.97e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—VCAN—melanoma	8.13e-06	1.97e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—HRAS—melanoma	8.12e-06	1.96e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MMP9—melanoma	8.11e-06	1.96e-05	CbGpPWpGaD
Dipyridamole—PDE4A—GPCR downstream signaling—AKT1—melanoma	8.11e-06	1.96e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—ERBB2—melanoma	8.1e-06	1.96e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—IL6—melanoma	8.1e-06	1.96e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—CDKN1A—melanoma	8.08e-06	1.95e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—STAT3—melanoma	8.07e-06	1.95e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PTEN—melanoma	8.07e-06	1.95e-05	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—AKT1—melanoma	8.06e-06	1.95e-05	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—AKT1—melanoma	8.06e-06	1.95e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NRAS—melanoma	8.05e-06	1.95e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CASP3—melanoma	8.04e-06	1.94e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—FGF2—melanoma	8.03e-06	1.94e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NFKB1—melanoma	8.03e-06	1.94e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL2—melanoma	8.03e-06	1.94e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PIK3CA—melanoma	8.02e-06	1.94e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—MAPK1—melanoma	8.02e-06	1.94e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—MAPK1—melanoma	8.02e-06	1.94e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—EGFR—melanoma	8.02e-06	1.94e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—EGFR—melanoma	8.02e-06	1.94e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CB—melanoma	7.99e-06	1.93e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—IL6—melanoma	7.99e-06	1.93e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—IL6—melanoma	7.99e-06	1.93e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CDKN1B—melanoma	7.98e-06	1.93e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—MAPK1—melanoma	7.94e-06	1.92e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—EGFR—melanoma	7.94e-06	1.92e-05	CbGpPWpGaD
Dipyridamole—PDE3A—GPCR downstream signaling—AKT1—melanoma	7.89e-06	1.91e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—AKT1—melanoma	7.87e-06	1.9e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CCND1—melanoma	7.82e-06	1.89e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CASP3—melanoma	7.82e-06	1.89e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL2—melanoma	7.81e-06	1.89e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—IL6—melanoma	7.79e-06	1.88e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—IL6—melanoma	7.77e-06	1.88e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CTNNB1—melanoma	7.75e-06	1.87e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MAPK3—melanoma	7.71e-06	1.86e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CXCL8—melanoma	7.68e-06	1.86e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—HRAS—melanoma	7.63e-06	1.84e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CCND1—melanoma	7.61e-06	1.84e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MMP9—melanoma	7.6e-06	1.84e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—KRAS—melanoma	7.57e-06	1.83e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—KRAS—melanoma	7.57e-06	1.83e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—CDKN1A—melanoma	7.57e-06	1.83e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PTEN—melanoma	7.55e-06	1.83e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—PIK3CA—melanoma	7.54e-06	1.82e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CTNNB1—melanoma	7.54e-06	1.82e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—PIK3CA—melanoma	7.54e-06	1.82e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NFKB1—melanoma	7.51e-06	1.82e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MDM2—melanoma	7.51e-06	1.82e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—KRAS—melanoma	7.5e-06	1.81e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CDKN1B—melanoma	7.5e-06	1.81e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MYC—melanoma	7.5e-06	1.81e-05	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—AKT1—melanoma	7.47e-06	1.81e-05	CbGpPWpGaD
Dipyridamole—PDE1A—GPCR downstream signaling—AKT1—melanoma	7.42e-06	1.79e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—ERBB2—melanoma	7.41e-06	1.79e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MMP9—melanoma	7.39e-06	1.79e-05	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—AKT1—melanoma	7.37e-06	1.78e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—AKT1—melanoma	7.37e-06	1.78e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—CDKN1A—melanoma	7.36e-06	1.78e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CASP3—melanoma	7.35e-06	1.78e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PTEN—melanoma	7.35e-06	1.78e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL2—melanoma	7.34e-06	1.77e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—MAPK1—melanoma	7.33e-06	1.77e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—EGFR—melanoma	7.33e-06	1.77e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NFKB1—melanoma	7.31e-06	1.77e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CB—melanoma	7.31e-06	1.77e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—IL6—melanoma	7.3e-06	1.77e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—VEGFA—melanoma	7.28e-06	1.76e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—STAT3—melanoma	7.21e-06	1.74e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NRAS—melanoma	7.2e-06	1.74e-05	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—AKT1—melanoma	7.18e-06	1.74e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—AKT1—melanoma	7.17e-06	1.73e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CCND1—melanoma	7.16e-06	1.73e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CTNNB1—melanoma	7.09e-06	1.71e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	7.03e-06	1.7e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CXCL8—melanoma	7.02e-06	1.7e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—HRAS—melanoma	6.98e-06	1.69e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—HRAS—melanoma	6.97e-06	1.69e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PIK3CA—melanoma	6.96e-06	1.68e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PIK3CA—melanoma	6.96e-06	1.68e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MMP9—melanoma	6.95e-06	1.68e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—KRAS—melanoma	6.93e-06	1.67e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—CDKN1A—melanoma	6.92e-06	1.67e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PTEN—melanoma	6.91e-06	1.67e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—PIK3CA—melanoma	6.89e-06	1.67e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MAPK3—melanoma	6.89e-06	1.67e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NFKB1—melanoma	6.87e-06	1.66e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP17A1—melanoma	6.86e-06	1.66e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CDKN1B—melanoma	6.86e-06	1.66e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—VEGFA—melanoma	6.82e-06	1.65e-05	CbGpPWpGaD
Dipyridamole—PDE1B—GPCR downstream signaling—AKT1—melanoma	6.79e-06	1.64e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—STAT3—melanoma	6.75e-06	1.63e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—AKT1—melanoma	6.74e-06	1.63e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NRAS—melanoma	6.74e-06	1.63e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CASP3—melanoma	6.72e-06	1.63e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL2—melanoma	6.71e-06	1.62e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MYC—melanoma	6.7e-06	1.62e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—IL6—melanoma	6.68e-06	1.61e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL6—melanoma	6.67e-06	1.61e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—VEGFA—melanoma	6.63e-06	1.6e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—STAT3—melanoma	6.57e-06	1.59e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—MAPK1—melanoma	6.56e-06	1.58e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—EGFR—melanoma	6.56e-06	1.58e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NRAS—melanoma	6.55e-06	1.58e-05	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—AKT1—melanoma	6.55e-06	1.58e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CCND1—melanoma	6.54e-06	1.58e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CTNNB1—melanoma	6.48e-06	1.57e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GNA11—melanoma	6.48e-06	1.57e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MAPK3—melanoma	6.45e-06	1.56e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—HRAS—melanoma	6.44e-06	1.56e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—HRAS—melanoma	6.44e-06	1.56e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—HRAS—melanoma	6.38e-06	1.54e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PIK3CA—melanoma	6.36e-06	1.54e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MMP9—melanoma	6.35e-06	1.54e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	6.35e-06	1.54e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—FASN—melanoma	6.34e-06	1.53e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—CDKN1A—melanoma	6.33e-06	1.53e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PTEN—melanoma	6.32e-06	1.53e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NFKB1—melanoma	6.29e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MAPK3—melanoma	6.28e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MYC—melanoma	6.28e-06	1.52e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—VEGFA—melanoma	6.24e-06	1.51e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—SLC5A5—melanoma	6.24e-06	1.51e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KRAS—melanoma	6.19e-06	1.5e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—STAT3—melanoma	6.18e-06	1.49e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—AKT1—melanoma	6.16e-06	1.49e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NRAS—melanoma	6.16e-06	1.49e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—IL6—melanoma	6.16e-06	1.49e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—IL6—melanoma	6.16e-06	1.49e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—AKT1—melanoma	6.16e-06	1.49e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—MAPK1—melanoma	6.14e-06	1.48e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—EGFR—melanoma	6.14e-06	1.48e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MYC—melanoma	6.1e-06	1.48e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL6—melanoma	6.1e-06	1.48e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—GNAQ—melanoma	6.02e-06	1.46e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CD44—melanoma	6.02e-06	1.46e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—MAPK1—melanoma	5.97e-06	1.44e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—EGFR—melanoma	5.97e-06	1.44e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MAPK3—melanoma	5.9e-06	1.43e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—HRAS—melanoma	5.89e-06	1.42e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PIK3CA—melanoma	5.83e-06	1.41e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KRAS—melanoma	5.8e-06	1.4e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CYP1B1—melanoma	5.78e-06	1.4e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MYC—melanoma	5.74e-06	1.39e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—VEGFA—melanoma	5.71e-06	1.38e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—PIK3CA—melanoma	5.69e-06	1.38e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—AKT1—melanoma	5.68e-06	1.37e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—AKT1—melanoma	5.68e-06	1.37e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—STAT3—melanoma	5.65e-06	1.37e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KRAS—melanoma	5.64e-06	1.36e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NRAS—melanoma	5.64e-06	1.36e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—IL6—melanoma	5.63e-06	1.36e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—AKT1—melanoma	5.63e-06	1.36e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—MAPK1—melanoma	5.61e-06	1.36e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—EGFR—melanoma	5.61e-06	1.36e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TP53—melanoma	5.5e-06	1.33e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MAPK3—melanoma	5.4e-06	1.3e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—PIK3CA—melanoma	5.33e-06	1.29e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KRAS—melanoma	5.3e-06	1.28e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—HRAS—melanoma	5.26e-06	1.27e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MYC—melanoma	5.25e-06	1.27e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—AKT1—melanoma	5.2e-06	1.26e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—PIK3CA—melanoma	5.18e-06	1.25e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TP53—melanoma	5.15e-06	1.25e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—MAPK1—melanoma	5.14e-06	1.24e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—EGFR—melanoma	5.13e-06	1.24e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL6—melanoma	5.04e-06	1.22e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TP53—melanoma	5.01e-06	1.21e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—HRAS—melanoma	4.93e-06	1.19e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PIK3CA—melanoma	4.87e-06	1.18e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KRAS—melanoma	4.85e-06	1.17e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—HRAS—melanoma	4.79e-06	1.16e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—AKT1—melanoma	4.76e-06	1.15e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL6—melanoma	4.72e-06	1.14e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TP53—melanoma	4.71e-06	1.14e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—AKT1—melanoma	4.65e-06	1.12e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL6—melanoma	4.59e-06	1.11e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—HRAS—melanoma	4.51e-06	1.09e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PIK3CA—melanoma	4.46e-06	1.08e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PRKCA—melanoma	4.38e-06	1.06e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—AKT1—melanoma	4.35e-06	1.05e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ERCC2—melanoma	4.34e-06	1.05e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL6—melanoma	4.31e-06	1.04e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TP53—melanoma	4.31e-06	1.04e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—AKT1—melanoma	4.23e-06	1.02e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—HRAS—melanoma	4.12e-06	9.97e-06	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—AKT1—melanoma	3.98e-06	9.62e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL6—melanoma	3.95e-06	9.54e-06	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—AKT1—melanoma	3.64e-06	8.8e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CG—melanoma	3.43e-06	8.29e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PPARG—melanoma	3.31e-06	8e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CD—melanoma	3.01e-06	7.28e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ALB—melanoma	2.98e-06	7.19e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CB—melanoma	2.63e-06	6.35e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTGS2—melanoma	2.6e-06	6.29e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTEN—melanoma	2.27e-06	5.49e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PIK3CA—melanoma	1.6e-06	3.87e-06	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—AKT1—melanoma	1.31e-06	3.16e-06	CbGpPWpGaD
